Single Dose of Antibiotic Found Effective in Quelling MRSA - NYTimes.com
Any questions about thoroughness of the research and lack or any bias?
"The study was led by researchers at Duke University and designed and funded by the Medicines Company, the maker of the antibiotic, oritavancin. The drug, to be sold as Orbactiv, may be approved by the Food and Drug Administration as early as August under a special fast-track process, the company said." Hope it works well but if it adds to the problem of drug resistant bacteria - this model of research must change.